![Stephan Oehen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stephan Oehen
Fondateur chez Priothera Ltd.
Postes actifs de Stephan Oehen
Sociétés | Poste | Début | Fin |
---|---|---|---|
Oehen Pr | Corporate Officer/Principal | - | - |
Priothera SAS
![]() Priothera SAS BiotechnologyHealth Technology Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020. | Directeur des opérations | 30/09/2020 | - |
Fondateur | 30/09/2020 | - | |
Priothera Ltd.
![]() Priothera Ltd. BiotechnologyHealth Technology Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland. | Directeur des opérations | 01/01/2020 | - |
Fondateur | 01/01/2020 | - |
Historique de carrière de Stephan Oehen
Anciens postes connus de Stephan Oehen
Sociétés | Poste | Début | Fin |
---|---|---|---|
Grayling Schweiz AG | Directeur Général | 01/01/2011 | 01/01/2013 |
Investinswitzerland | Fondateur | - | - |
POWERLAND AG | Directeur/Membre du Conseil | 26/03/2014 | - |
Statistiques
Internationale
Suisse | 4 |
Allemagne | 2 |
Irlande | 2 |
Opérationnelle
Founder | 3 |
Chief Operating Officer | 2 |
Director/Board Member | 1 |
Sectorielle
Health Technology | 3 |
Consumer Non-Durables | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 6 |
---|---|
Powerland AG
![]() Powerland AG Consumer SundriesConsumer Non-Durables Powerland AG engages in the design, production, marketing and sale of bags and other textile and leather products. The company was founded in 2003 and is headquartered in Frankfurt, Germany. | Consumer Non-Durables |
Oehen Pr | |
Investinswitzerland | |
Grayling Schweiz AG | |
Priothera Ltd.
![]() Priothera Ltd. BiotechnologyHealth Technology Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland. | Health Technology |
Priothera SAS
![]() Priothera SAS BiotechnologyHealth Technology Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020. | Health Technology |
- Bourse
- Insiders
- Stephan Oehen
- Expérience